HOXB5 and acute myeloid leukemia: The AML patients with FLT3, NPM1, and DNMT3A (FND) triple mutations exhibited higher HOXB5 expression levels than AML patients with one or two gene mutations, whereas triple-negative AML patients (without any FLT3, NPM1, or DNMT3A mutations) showed the lowest HOXB5 expression levels (Figure 2B and Supplementary Figure 4B).